Clinical Decision
Pathway Navigator
Select etiology → tap decision node → retrieve guideline recommendation
1
Initial Evaluation Complete?
Comprehensive H&P · CT chest+neck · Labs · Airway parameters
Good Practice Statement — Rec 1
Comprehensive H&P (symptoms, comorbidities, medications, prior thoracic surgery/chemoradiation). Airway parameters: mouth opening (>3 FB), Mallampati, ULBT, thyromental distance (>3 FB), neck mobility (>90°), dentition, cervical spine. CT chest+neck = imaging of choice.
Evidence: Good Practice Statement · No comparator studies · CT preferred over plain radiograph (radiographic CAO diagnosis often missed or delayed)
2
Therapeutic bronchoscopy indicated?
Rec 2 · Conditional · Very Low
Therapeutic bronchoscopy as adjunct to systemic therapy ± local radiation. In malignant CAO, relieves obstruction enabling chemo-immunotherapy, targeted therapy, and radiation delivery.
Key evidence: Survival HR 2.1 (95% CI 1.1–4.8; p=0.003) favouring bronchoscopy + chemoradiation vs chemoradiation alone (n=100 retrospective). Prospective study (n=46): mean survival 10±9 months (bronchoscopy) vs 4±3 months (no bronchoscopy). Dyspnea reduction and QoL improvement at 6 months. Atelectasis and rehospitalisations decreased.
Therapeutic bronchoscopy as adjunct to systemic therapy ± local radiation. In malignant CAO, relieves obstruction enabling chemo-immunotherapy, targeted therapy, and radiation delivery.
Key evidence: Survival HR 2.1 (95% CI 1.1–4.8; p=0.003) favouring bronchoscopy + chemoradiation vs chemoradiation alone (n=100 retrospective). Prospective study (n=46): mean survival 10±9 months (bronchoscopy) vs 4±3 months (no bronchoscopy). Dyspnea reduction and QoL improvement at 6 months. Atelectasis and rehospitalisations decreased.
Use spirometry (FEV1/FVC) and flow-volume loop to quantify functional limitation. CT % lumen occlusion: ≥50% = CAO by definition. Track symptom trajectory and rate of progression to gauge urgency.
3
Rigid or Flexible Bronchoscopy?
Rec 3 · Conditional · Very Low
Prefer rigid bronchoscopy Evidence certainty: very low for proximal/critical obstruction. Advantages: ventilation conduit, "core-through" for bulky tumours, superior tamponade for airway haemorrhage, platform for rigid forceps and silicone stents. Flexible bronchoscope used as adjunct for distal airway interventions.
AQuIRE registry (n=947): success 93.5% (rigid) vs 92.7% (flexible); P=0.62 — not significant. Fewer sessions with rigid (1 vs 2; P<0.001). More bleeding-related deaths with flexible bronchoscopy in retrospective data.
Prefer rigid bronchoscopy Evidence certainty: very low for proximal/critical obstruction. Advantages: ventilation conduit, "core-through" for bulky tumours, superior tamponade for airway haemorrhage, platform for rigid forceps and silicone stents. Flexible bronchoscope used as adjunct for distal airway interventions.
AQuIRE registry (n=947): success 93.5% (rigid) vs 92.7% (flexible); P=0.62 — not significant. Fewer sessions with rigid (1 vs 2; P<0.001). More bleeding-related deaths with flexible bronchoscopy in retrospective data.
Flexible bronchoscopy may suffice for distal, accessible lesions. Similar success rates in registry data. Consider rigid scope with flexible adjunct as hybrid approach — particularly if haemorrhage risk is elevated.
4
Endobronchial (intrinsic) tumour?
Rec 6 · Conditional · Very Low
Perform tumour excision + ablation. Techniques: manual debridement (rigid/flexible forceps), rigid coring, cryodebridement, microdebridement — combined with heat ablation (laser, electrocautery, APC) for haemostasis.
Perform tumour excision + ablation. Techniques: manual debridement (rigid/flexible forceps), rigid coring, cryodebridement, microdebridement — combined with heat ablation (laser, electrocautery, APC) for haemostasis.
Fire safety: reduce FiO₂ to ≤0.4 before any heat ablative device activation. Keep catheters away from flammable materials.
Extrinsic compression without debridable endobronchial tissue. Consider early stent placement if oncologic response will be delayed. Radiation planning must account for metallic stent scatter and anatomic distortion.
5
Stent placement indicated?
Rec 8 · Conditional · Very Low
Stent is indicated if other modalities failed or extrinsic compression predominates conditional · very low certainty. Benefit highest in: failed first-line chemotherapy, receiving radiation/palliation (SPOC trial: HR 0.21; 95% CI 0.06–0.74; p=0.007 for local recurrence). AQuIRE: stent = technical success OR 11.9 (95% CI 5.1–27.8). More durable dyspnoea relief; fewer repeat bronchoscopies.
Stent is indicated if other modalities failed or extrinsic compression predominates conditional · very low certainty. Benefit highest in: failed first-line chemotherapy, receiving radiation/palliation (SPOC trial: HR 0.21; 95% CI 0.06–0.74; p=0.007 for local recurrence). AQuIRE: stent = technical success OR 11.9 (95% CI 5.1–27.8). More durable dyspnoea relief; fewer repeat bronchoscopies.
Avoid stent if debridement alone achieves adequate patency. Stent complications (mucus plugging, granulation tissue, migration, fracture, infection) add significant procedural burden. Reserve for failure of other modalities.
Rec 9 · Conditional · Very Low
Either routine surveillance or symptom-driven bronchoscopy is acceptable Evidence certainty: very low. Evidence: routine surveillance detected stent complications in 41% — but 84% of symptomatic patients had complications anyway. Adjuncts: hypertonic saline nebulisation (mucociliary clearance), CT for non-invasive stent/patency assessment.
Either routine surveillance or symptom-driven bronchoscopy is acceptable Evidence certainty: very low. Evidence: routine surveillance detected stent complications in 41% — but 84% of symptomatic patients had complications anyway. Adjuncts: hypertonic saline nebulisation (mucociliary clearance), CT for non-invasive stent/patency assessment.
6
Carcinoid or localised cancer — surgery?
Rec 12 · Conditional · Very Low
Surgery with curative intent is treatment of choice for carcinoid tumours. Therapeutic bronchoscopy bridges to surgery or serves as primary therapy if non-surgical. 5-year survival: bronchoscopic 94.4% vs surgical 94.5% (p=0.9) — comparable in one retrospective series.
Surgery with curative intent is treatment of choice for carcinoid tumours. Therapeutic bronchoscopy bridges to surgery or serves as primary therapy if non-surgical. 5-year survival: bronchoscopic 94.4% vs surgical 94.5% (p=0.9) — comparable in one retrospective series.
Limited evidence supporting surgery for non-carcinoid malignant CAO due to advanced locoregional/metastatic disease. Therapeutic bronchoscopy is primary modality. Systemic chemo-immunotherapy ± local radiation remain cornerstones.
Surgical resection may be considered if curative and patient is a surgical candidate. Therapeutic bronchoscopy can serve as bridge to definitive surgical resection for localised disease.
Pre-procedural Evaluation
Airway Assessment
Rigid bronchoscopy / endotracheal intubation risk stratification
Normal: >3 finger-breadths
Normal: >3 finger-breadths
Normal: >90°
Prominent, missing, or loose = rigid scope risk
Impacts rigid bronchoscopy positioning
Affects haemorrhage risk with ablation
Modified Mallampati Score
Upper Lip Bite Test (ULBT) & Lower Jaw Slide
Mandibular prognathism proxy
Assesses lower incisor ability to bite the upper lip — a proxy for mandibular protrusion capacity and TMJ mobility. Complements Mallampati; ULBT Class III independently predicts difficult laryngoscopy (specificity ~96%, LR+ ≈11).
Instruction: "Slide your lower jaw forward as far as possible and bite your upper lip."
Class I → normal; favourable for rigid bronchoscope passage
Class II → intermediate; have video laryngoscopy immediately available
Class III → high-risk (LR+ ≈11; spec ~96%); plan advanced airway strategy
Edentulous → ULBT not possible; use palpatory TMJ assessment
Class II → intermediate; have video laryngoscopy immediately available
Class III → high-risk (LR+ ≈11; spec ~96%); plan advanced airway strategy
Edentulous → ULBT not possible; use palpatory TMJ assessment
Airway Risk Profile
Complete fields above — risk profile builds automatically.
Note: This is a local heuristic for airway-access planning. It is not a validated predictor of CAO procedural outcome, mortality, or bronchoscopy complications.
🫁 Functional Assessment
Flow-volume loopFixed obstruction: plateau on both inspiratory and expiratory limbs
Variable extrathoracic: inspiratory plateau only
Variable intrathoracic: expiratory plateau only
SpirometryBaseline FEV1/FVC; monitor post-intervention response
CT % occlusion≥50% = CAO by definition; procedural success threshold = >50% reopening
Peri-procedural Management
Anaesthesia & Ventilation
Evidence-based selection of anaesthetic depth and ventilation mode
Depth of Anaesthesia — Evidence Comparison Rec 4 Evidence certainty: very low
GA / Deep Sedation Preferred
Complication riskLower · OR 0.42 (0.21–0.83; P=.013)
With paralytics3% complications vs 6.7% (P=.006)
Procedure sessionsFewer (patient tolerates longer procedures)
Desaturation eventsFewer with paralytics (RCT: Okamoto 2020)
Technical successNo significant difference vs moderate
Bleeding deathsLower
Moderate Sedation Conditional
Complication riskHigher (reference comparator)
Without paralytics6.7% complications
Procedure sessionsMore required
Desaturation eventsMore events
Technical successNo significant difference vs GA
Bleeding deathsHigher in retrospective data
Source: AQuIRE registry (n=1,115 procedures) · RCT Okamoto et al. Anesth Analg 2020;131:893–900 · Conditional, Very Low Certainty
Ventilation Mode During Rigid Bronchoscopy Rec 5
Jet Ventilation
TechniqueHigh-pressure O₂ bursts via open rigid scope
RateManual 10–14/min (Sanders) or HFJV 60–300/min
AQuIRE success96.1%
Complication rateLower vs controlled
HypercapniaLess than controlled ventilation
Controlled / Spontaneous Assisted
TechniqueSealed scope + anaesthesia circuit + PPV
Paralytic benefitSignificantly fewer intraop respiratory complications
AQuIRE success92.9%
HypercapniaMore significant vs jet (Duckett 1985)
NoteControlled preferred over spontaneous assisted
Either mode is acceptable — no significant difference in success, dyspnoea improvement, or complication-related mortality (AQuIRE). ECMO may be considered for critical bilateral mainstem or tracheal obstruction — patient selection criteria poorly defined; multidisciplinary decision required.
✅ Pre-procedure Safety Checklist
Airway assessment completed: Mallampati, ULBT, mouth opening, TMD, neck mobilityCervical spine, dentition, previous surgery/radiation noted in chart
CT chest+neck reviewed — anatomy, % occlusion, lesion type documentedIntrinsic / extrinsic / mixed classification established
Anaesthesiology team briefed — multidisciplinary plan agreedGA/deep sedation preferred; paralytics only if appropriate after individualized induction/ventilation planning
Anticoagulant/antiplatelet medications reviewed and managedBleeding risk stratification complete; reversal/bridging plan in place
Ventilation mode selected — equipment verified and testedSanders injector / HFJV machine available if jet chosen; seal tested if controlled
FiO₂ ≤0.4 protocol confirmed before ablation — stated aloud to teamCRITICAL: airway fire prevention checkpoint
Haemorrhage control plan in place: rigid scope tamponade, vasoconstrictors, suctionParticularly critical with heat ablation + endobronchial disease
Shared decision-making with patient/family documentedGoals of care, QoL priorities, stent risks, realistic outcomes discussed
0 / 8
Airway Stenting
Stent Decision
Structured assessment of indications, patient context, and complication profile
Step 1 — Can airway patency be achieved by debridement alone?
⚠️ Stent Complication Profile
| Complication | Notes | Prevention / Management |
|---|---|---|
| Mucus plugging | Most common; commoner with silicone stents | Hypertonic saline nebulisation, mucolytics, surveillance bronchoscopy |
| Granulation tissue | At stent ends; respiratory infections increase risk | Local ablation, stent repositioning |
| Stent migration | Subglottic/tracheal location; silicone > covered metal | Correct sizing; anatomical anchoring; special shapes |
| Stent fracture | Metal stents; long-term use | Surveillance CT/bronchoscopy |
| Infection / biofilm | Increases granulation tissue risk | Surveillance bronchoscopy; targeted antibiotics |
| Radiation scatter | Metal stents in radiotherapy field | Careful radiation planning; anatomic distortion documentation |
| FDA 2005 warning | Metallic stents in benign disease | Use fully covered metal or silicone; prefer bronchoscopic alternatives |
📅 Post-Stent Surveillance Rec 9 Evidence certainty: very low
Conditional · Very Low Certainty
Either routine surveillance or symptom-driven bronchoscopy is acceptable. Key data (Matsuo & Colt, Chest 2000): routine surveillance found complications in 41% — nearly all symptomatic. Symptom-driven group: 84% were symptomatic at time of complication detection. A symptom-driven approach may reduce procedural burden when supported by patient education and reliable follow-up.
Adjuncts: hypertonic saline nebulisation (mucociliary clearance) · CT chest for non-invasive stent/patency assessment · Patient education on warning symptoms (dyspnoea ↑, purulent sputum, fever, haemoptysis)
Guideline Summary
Evidence Atlas
CHEST 2025 CAO recommendations — strength, certainty, key statistics
The guideline includes one Good Practice Statement and graded conditional recommendations, with overall Very Low certainty of evidence. Evidence base: 31 studies identified from 9,688 screened abstracts. 150 full-text articles assessed.
| Rec | Domain | Recommendation (summary) | Strength | Certainty | Key statistic |
|---|---|---|---|---|---|
| 1 | Evaluation | Comprehensive H&P + CT chest+neck + labs | Good Practice | — | CT = imaging of choice; Mallampati, ULBT, TMD, mouth opening, neck mobility |
| 2 | Bronchoscopy | Therapeutic bronchoscopy as adjunct to systemic therapy ± radiation | Conditional | Very Low | Survival HR 2.1 (95% CI 1.1–4.8; p=0.003) favoring bronchoscopy + CRT vs CRT alone |
| 3 | Rigid vs flexible | Prefer rigid bronchoscopy for therapeutic interventions | Conditional | Very Low | AQuIRE: 93.5% vs 92.7% success (P=.62); fewer sessions rigid (1 vs 2; P<0.001) |
| 4 | Anaesthesia depth | GA/deep sedation preferred over moderate sedation; paralytics individualized | Conditional | Very Low | OR 0.42 (0.21–0.83) complications; paralytics 3% vs 6.7% (P=.006) |
| 5 | Ventilation mode | Either jet ventilation or controlled/spontaneous assisted | Conditional | Very Low | AQuIRE: 96.1% (jet) vs 92.9% (controlled); no significant difference in complications |
| 6 | Excision/ablation | Tumour/tissue excision ± ablation for endobronchial disease | Conditional | Very Low | ERMT vs dilation at 5yr: 30% vs 50% recurrence (idiopathic subglottic stenosis) |
| 7 | Dilation | Airway dilation alone or combined for nonmalignant stenosis | Conditional | Very Low | Dilation 50% recurrence at 5yr; ERMT HR 3.16 (1.82–5.51) fewer recurrences vs dilation |
| 8 | Stent | Stent indicated if other treatments failed and when feasible | Conditional | Very Low | SPOC trial: HR 0.21 (0.06–0.74; p=0.007) in failed-chemo/palliative group; AQuIRE OR 11.9 technical success |
| 9 | Stent surveillance | Routine or symptom-driven surveillance bronchoscopy | Conditional | Very Low | Routine: 41% complications detected; 84% of symptomatic patients had complications regardless |
| 10 | Local therapy | Either use or hold local (non-ablative) bronchoscopic therapy | Conditional | Very Low | Mitomycin C: 75% 4-month success vs 18.2% steroid vs 15% dilation alone |
| 11 | Surgery (nonmal) | Either surgical resection or therapeutic bronchoscopy | Conditional | Very Low | 5-year recurrence: surgery 5%, ERMT 30%, dilation 50% (idiopathic subglottic stenosis; n=487) |
| 12 | Surgery (mal) | Either surgery or bronchoscopy; curative intent surgery for carcinoid | Conditional | Very Low | Carcinoid 5-yr survival: bronchoscopic 94.4% vs surgical 94.5% (P=0.9) |
🔬 Research Gaps — Teaching Priorities
1. RCTs comparing therapeutic bronchoscopy vs radiation/combined modalities — ethical challenge given existing evidence
2. Flexible vs rigid bronchoscopy for proximal vs distal CAO — prospective safety/efficacy data
3. GA/deep sedation vs moderate sedation — formal comparative trial
4. ECMO indications for critical bilateral mainstem/tracheal obstruction — patient selection criteria
5. Comparative effectiveness of ablative modalities: laser vs electrocautery vs APC vs cryo
6. New-generation fully covered metal stents in benign disease (post-FDA 2005 warning)
7. Drug-coated and 3D-printed stents — clinical evaluation
8. Optimal local bronchoscopic therapy agents and schedules
9. Surgery vs bronchoscopy in CAO — patient-centric outcomes (QoL, voice, breathing, survival)
2. Flexible vs rigid bronchoscopy for proximal vs distal CAO — prospective safety/efficacy data
3. GA/deep sedation vs moderate sedation — formal comparative trial
4. ECMO indications for critical bilateral mainstem/tracheal obstruction — patient selection criteria
5. Comparative effectiveness of ablative modalities: laser vs electrocautery vs APC vs cryo
6. New-generation fully covered metal stents in benign disease (post-FDA 2005 warning)
7. Drug-coated and 3D-printed stents — clinical evaluation
8. Optimal local bronchoscopic therapy agents and schedules
9. Surgery vs bronchoscopy in CAO — patient-centric outcomes (QoL, voice, breathing, survival)
Formative Assessment
Resident Quiz
10 high-yield questions from ACCP CAO 2025 guideline
Documentation
Case Context & Automated Output
Complete after using the decision tabs. Timestamp is generated automatically in Copy / Save TXT / Print outputs.